Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid

BACKGROUND: Early and accurate detection and staging is critical to managing Alzheimer’s disease (AD) and supporting clinical trials. Cerebrospinal fluid (CSF) biomarkers for amyloid-β peptides, tau species, and various neurodegenerative and inflammatory analytes are leading the way in this regard,...

Descripción completa

Detalles Bibliográficos
Autores principales: Triana-Baltzer, Gallen, Van Kolen, Kristof, Theunis, Clara, Moughadam, Setareh, Slemmon, Randy, Mercken, Marc, Galpern, Wendy, Sun, Hong, Kolb, Hartmuth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683057/
https://www.ncbi.nlm.nih.gov/pubmed/32831201
http://dx.doi.org/10.3233/JAD-200463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683057/
https://www.ncbi.nlm.nih.gov/pubmed/32831201
http://dx.doi.org/10.3233/JAD-200463

Ejemplares similares